logo

ALNYLAM PHARMACEUTICALS INC

Alnylam’s Dual‑Mechanism Therapy Hits Key Milestones, Poised to Transform Chronic Hepatitis Delta Treatment

Alnylam’s Dual‑Mechanism Therapy Hits Key Milestones, Poised to Transform Chronic Hepatitis Delta Treatment

Alnylam’s dual‑mechanism therapy for chronic hepatitis delta hits key virologic milestones, offering durable viral suppression and improved liver health with a single monthly injection—transformative potential for an orphan disease.
3 minutes to read